Malignant uveal melanoma is the commonest primary intraocular tumour in adu
lts. It metastasizes frequently and 50% of patients die within 10 years of
diagnosis. The expression of cyclin D1, p53, and MDM2 in uveal melanoma and
their relationship to metastasis-free 5-year survival was determined, in o
rder to investigate whether these proteins help to distinguish those patien
ts with a favourable prognosis from those with a poorer one. Ninety-six eye
s enucleated for uveal melanomas were immunohistochemically analysed for th
e protein expression of cyclin D1 and related cell-cycle markers, p53 and M
DM2, The evaluation of the specimens was undertaken by two independent path
ologists without knowledge of the outcome. Statistical analysis of clinical
, morphological, and immunohistological features was performed. A 'favourab
le outcome' was defined as survival of at least 5 years after diagnosis, wi
thout metastases (n = 57). An 'unfavourable outcome' was defined as death f
rom metastases within the first 5 years after diagnosis of meal melanoma (n
= 39), Cyclin D1 positivity (>15% positive tumour cells) as well as p53 po
sitivity(>15% positive tumour cells) was associated with an unfavourable ou
tcome (for cyclin D1: odds ratio = 4.2, 95% confidence interval 1.5-11.8, p
= 0.006; for p53: odds ratio = 3.2, 95% confidence interval 1.1-9.3, p = 0
.03). In addition, cyclin D1 positivity was associated with the presence of
extraocular extension of the tumour (p = 0.01), with the mixed or epitheli
oid cell type (p = 0.02), and with the tumour cell MIB-1 positivity (p = 0.
0001). MDM2 immunoreactivity of the tumour cells showed a potential correla
tion with clinical outcome (odds ratio = 2.1, 95% confidence interval 0.8-5
.8, p = 0.13). Multiple logistic regression models showed that cyclin D1 po
sitivity is an independent prognostic factor after control for other progno
stic markers, The expression of cyclin D1 in uveal melanoma is associated w
ith a more aggressive course and histologically unfavourable disease. This
could serve as a further independent prognostic factor in uveal melanoma, C
opyright (C) 2000 John Wiley & Sons, Ltd.